Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Limited has issued 1,500,000 fully paid ordinary shares following the exercise of unlisted options, allowing these shares to be traded immediately. This move is part of the company’s compliance with the Corporations Act, potentially enhancing its market operations and providing liquidity for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell is a regenerative medicine company specializing in products for repairing bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, with products like Striate+™ and Remplir™ cleared for use in multiple countries. The company is also advancing its tendon cell therapy in the US.
Average Trading Volume: 613,710
Technical Sentiment Signal: Buy
Current Market Cap: A$292.5M
Learn more about OCC stock on TipRanks’ Stock Analysis page.